WO1998001570A3 - Mutated antibody-dependent infection enhancing domains of hiv - Google Patents

Mutated antibody-dependent infection enhancing domains of hiv Download PDF

Info

Publication number
WO1998001570A3
WO1998001570A3 PCT/US1997/011667 US9711667W WO9801570A3 WO 1998001570 A3 WO1998001570 A3 WO 1998001570A3 US 9711667 W US9711667 W US 9711667W WO 9801570 A3 WO9801570 A3 WO 9801570A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
antibody
mutated antibody
dependent
dependent infection
Prior art date
Application number
PCT/US1997/011667
Other languages
French (fr)
Other versions
WO1998001570A2 (en
Inventor
William M Mitchell
Original Assignee
Univ Vanderbilt
William M Mitchell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt, William M Mitchell filed Critical Univ Vanderbilt
Priority to AU36501/97A priority Critical patent/AU3650197A/en
Publication of WO1998001570A2 publication Critical patent/WO1998001570A2/en
Publication of WO1998001570A3 publication Critical patent/WO1998001570A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

HIV virus mutants having an alteration which inhibits induction of enhancing antibody to said virus are described. Also described are HIV virus mutants in which an antibody-dependent enhancing domain in gp41 includes amino acid alterations. Also described are HIV vaccines comprising HIV gp160 mutants in which an antibody-dependent enhancing domain in gp41 includes at least one amino acid alteration.
PCT/US1997/011667 1996-07-05 1997-07-02 Mutated antibody-dependent infection enhancing domains of hiv WO1998001570A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU36501/97A AU3650197A (en) 1996-07-05 1997-07-02 Mutated antibody-dependent infection enhancing domains of hiv

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2166896P 1996-07-05 1996-07-05
US60/021,668 1996-07-05

Publications (2)

Publication Number Publication Date
WO1998001570A2 WO1998001570A2 (en) 1998-01-15
WO1998001570A3 true WO1998001570A3 (en) 1998-02-26

Family

ID=21805497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/011667 WO1998001570A2 (en) 1996-07-05 1997-07-02 Mutated antibody-dependent infection enhancing domains of hiv

Country Status (2)

Country Link
AU (1) AU3650197A (en)
WO (1) WO1998001570A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369119A1 (en) 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
WO2013026452A1 (en) * 2011-08-23 2013-02-28 Skau Aps Method for removing immunosuppresive properties of hiv envelope glycoproteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019510A (en) * 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
WO1995007987A2 (en) * 1993-09-16 1995-03-23 Solvay S.A. Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor
WO1997014442A1 (en) * 1995-10-18 1997-04-24 Merlin Technologies, Inc. Hormone immunomodulated induction of mucosal immune responses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019510A (en) * 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
WO1995007987A2 (en) * 1993-09-16 1995-03-23 Solvay S.A. Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor
WO1997014442A1 (en) * 1995-10-18 1997-04-24 Merlin Technologies, Inc. Hormone immunomodulated induction of mucosal immune responses

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
J.R MASCOLA ET AL.: "Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 9, no. 12, December 1993 (1993-12-01), NEW YORK US, pages 1175 - 1184, XP002049761 *
MITCHELL W M ET AL: "Induction of mucosal anti-HIV antibodies by facilitated transfection of airway epithelium with lipospermine/DNA complexes", IMMUNOTECHNOLOGY, vol. 1, no. 3, December 1995 (1995-12-01), AMSTERDAM NL, pages 211-219, XP004052723 *
P. AUEWARAKUL ET AL.: "Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand", VIRAL IMMUNOLOGY, vol. 9, no. 3, March 1996 (1996-03-01), US, pages 175 - 185, XP002049758 *
S.B. JIANG ET AL: "Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp140/gp41", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 174, no. 6, 1 December 1991 (1991-12-01), NEW YORK US, pages 1557 - 1563, XP002049759 *
S.C. KLIKS ET AL.: "V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 90, December 1993 (1993-12-01), WASHINGTON US, pages 11518 - 11522, XP002049757 *
W.E. ROBINSON JR ET AL.: "Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro", JOURNAL OF VIROLOGY., vol. 64, no. 11, November 1990 (1990-11-01), BALTIMORE US, pages 5301 - 5305, XP002049760 *

Also Published As

Publication number Publication date
AU3650197A (en) 1998-02-02
WO1998001570A2 (en) 1998-01-15

Similar Documents

Publication Publication Date Title
WO1999033868A3 (en) Human papillomavirus vaccine
NZ237666A (en) Hiv envelope (env) polypeptides, antibodies and compositions for treating aids
EP0608261A4 (en) Immunoreactive hepatitis c virus polypeptide compositions.
EP1526173A3 (en) Compositions comprising viruses and methods for concentrating virus preparations
EP1325957A3 (en) Recombinant papilloma virus L1
DE59402827D1 (en) METHOD FOR OBTAINING NATIVE, OLIGOMERIC, GLYCOSYLATED EKTODOMÄNEN VIRAL MEMBRANE PROTEINS, THEIR USE, ESPECIALLY AS A VACCINE AGAINST HIV
WO2000000616A3 (en) Marburg virus vaccines
AUPO784197A0 (en) Treatment of nasopharyngeal carcinoma
WO1993014208A3 (en) Hepatitis e virus vaccine and method
AU2197392A (en) Hepatitis C virus from C-100-3 and env/core regions
MC2308A1 (en) PEPTIDES FOR VACCINATION AND INDUCTION OF NEUTRALIZING ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS
EP1375511A3 (en) Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
AU1463097A (en) Helicobacter pylori bacterioferritin
TR199701051A2 (en) Preparation process of 2'-Fluoro-5-methyl-β-1-arabino-furanosylridine
ATE267256T1 (en) HEPATIS E VIRUS ANTIGENS AND THEIR USES
AU8010791A (en) Hiv monoclonal antibody
CA2351315A1 (en) Humanized antibody specific for surface antigen pre-s1 of hbv and preparation method thereof
WO1998001570A3 (en) Mutated antibody-dependent infection enhancing domains of hiv
EP1057889A4 (en) Enhanced immunogen for inactivated vaccine for infection with japanese encephalitis viruses and process for producing the same
EP1104310A4 (en) Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
WO2002022687A3 (en) Viral chemokine-tumur antigen fusion proteins
EP1326895B8 (en) Monoclonal antibodies directed against hepatitis b viruses
AU2370592A (en) Epitopes of the env protein of the hepatitis c virus
HUP0001991A2 (en) Vaccines against varicella zoster virus gene 63 product
EP0314240A3 (en) Process for purifying recombinant hepatitis antigens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 98505280

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase